Evidence memo / Anabolic androgens & PEDs

Turinabol

Also: chlorodehydromethyltestosterone · oral turinabol · CDMT · tbol

The drug at the centre of the East German state doping programme, administered to athletes including minors without their knowledge, and the source of the best long-term follow-up data anyone has on what these compounds do decades later.

Claim-specific / contestedContext-dependentSafety / regulatory watch

The verdict

Our read at a glance.

What decades of follow-up on a population given this compound systematically actually shows.

The signal
Its history is the evidence. Turinabol was the principal agent in a state-run doping programme administered to thousands of athletes, many of them adolescent girls, frequently without informed consent. That cohort has been followed, and the reported consequences include virilisation, gynaecological and reproductive harm, psychiatric morbidity and musculoskeletal injury - an unusually long-horizon dataset that exists only because of the scale and documentation of the programme. The modern scientific literature is dominated by anti-doping chemistry: turinabol's long-term metabolites are detectable for an exceptionally long period, and their characterisation led to retrospective reanalysis of stored samples and a wave of retrospective disqualifications.
The unknown
How much of the East German cohort's harm is attributable to turinabol specifically rather than to the polypharmacy and the training regime around it. The natural experiment was not designed as one.
Our read
The compound with the best long-term human outcome data in the entire class, and it exists because a state administered it to children. Anyone describing turinabol as mild should sit with what the follow-up literature on that cohort actually documents.

The mechanism

How it works.

Turinabol is methandienone with a chlorine atom added at the 4-position. That single substitution blocks aromatisation, so unlike its parent compound it produces no oestradiol - the basis of the dry, non-bloating reputation. It retains the 17-alpha methyl group, so it is orally active and carries the hepatic liability and HDL suppression that go with 17-alpha alkylation. Its androgen receptor binding is relatively modest and it binds sex hormone binding globulin strongly, which raises free levels of other circulating androgens - part of why it was used in combination. The feature that made it forensically famous is metabolic: turinabol produces long-term metabolites that persist in urine far longer than the parent compound, which is why stored samples could be reanalysed years later once the metabolites were characterised.

Safety & regulatory boundary

The consequential part.

No approved human product; a Schedule III controlled substance. 17-alpha-alkylated and therefore hepatotoxic with the characteristic effects on HDL. Non-aromatising, so it produces no oestrogen, which removes oestrogenic side effects and also removes oestrogen's protective role. Prohibited in sport, with an unusually long detection window that has caught athletes years after use.

What's next

What we're watching.

Continued follow-up of the East German cohort, which remains the longest-horizon human data available on anabolic steroid exposure.

Context

Why this is discussed.

It has a reputation as a mild oral with clean gains and no oestrogenic effects, and it carries the mystique of the East German programme's results.

The evidence base

12 cited references.

Indexed literature (PubMed)12

Solid forms and β-cyclodextrin complexation of turinabol

Turza A et al. · Acta Crystallogr C Struct Chem · 2022

Metabolism of oral turinabol by the human brain cholesterol 24-hydroxylase CYP46A1

Putkaradze N et al. · J Steroid Biochem Mol Biol · 2021

Metabolic studies of turinabol in horses

Ho EN et al. · Anal Chim Acta · 2007

Keep reading

Related published memos.